Rocket Pharmaceuticals (RCKT) Current Deferred Revenue (2018 - 2023)

Rocket Pharmaceuticals has disclosed Current Deferred Revenue across 6 years of filings, most recently posting $597000.0 for Q2 2023.

• Current Deferred Revenue for Q2 2023 came in at $597000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Jun 2023 was $597000.0 (changed 0.0% YoY), and the FY2022 annual result was $597000.0, changed 0.0% from the prior year.
• Current Deferred Revenue came in at $597000.0 for Q2 2023 at Rocket Pharmaceuticals, roughly flat from $597000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $597000.0 in Q1 2021 to a low of $541000.0 in Q1 2019.
• The 5-year median for Current Deferred Revenue is $597000.0 (2021), against an average of $583000.0.
• Across the five-year window, Current Deferred Revenue advanced 5.46% in 2019 and changed 0.0% in 2022, its largest moves.
• Rocket Pharmaceuticals' Current Deferred Revenue stood at $562000.0 in 2019, then increased by 4.98% to $590000.0 in 2020, then advanced by 1.19% to $597000.0 in 2021, then changed by 0.0% to $597000.0 in 2022, then changed by 0.0% to $597000.0 in 2023.
• The last three Current Deferred Revenue figures came in at $597000.0 (Q2 2023), $597000.0 (Q1 2023), and $597000.0 (Q4 2022), per Business Quant data.